<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0803210590
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SINGULAIR PAEDIATRIC 4 MG CHEWABLE TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MONTELUKAST SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Chewable tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        111.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MERCK SHARP &amp; DOHME" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MERCK SHARP & DOHME
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Organon Pharma UK Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Singulair Paediatric is a leukotriene receptor antagonist that blocks substances called leukotrienes.</p><p>&nbsp;</p><p>How Singulair Paediatric works</p><p>Leukotrienes cause narrowing and swelling of airways in the lungs. By blocking leukotrienes, Singulair Paediatric improves asthma symptoms and helps control asthma.</p><p>&nbsp;</p><p>When Singulair Paediatric should be used</p><p>Your doctor has prescribed Singulair Paediatric to treat your child&rsquo;s asthma, preventing asthma symptoms during the day and night.</p><p>&nbsp;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Singulair Paediatric is used for the treatment of 2 to 5 year old patients who are not adequately controlled on their medication and need additional therapy.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Singulair Paediatric may also be used as an alternative treatment to inhaled corticosteroids for 2 to 5 year old patients who have not recently taken oral corticosteroids for their asthma and have shown that they are unable to use inhaled corticosteroids.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Singulair Paediatric also helps prevent the narrowing of airways triggered by exercise for patients 2 years of age and older.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Singulair Paediatric is used to treat outdoor allergies that happen part of the year (seasonal allergic rhinitis) in children 2 to 5 years of age</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Singulair Paediatric is used to treat indoor allergies that happen all year (perennial allergic rhinitis) in children 2 to 5 years of age.</p><p>Your doctor will determine how Singulair Paediatric should be used depending on the symptoms and severity of your child&#39;s asthma.</p><p>&nbsp;</p><p>What is asthma?</p><p>Asthma is a long-term disease. Asthma includes:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->difficulty breathing because of narrowed airways. This narrowing of airways worsens and improves in response to various conditions.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sensitive airways that react to many things, such as cigarette smoke, pollen, cold air, or exercise.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->swelling (inflammation) in the lining of the airways.</p><p>&nbsp;</p><p>Symptoms of asthma include: Coughing, wheezing, and chest tightness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor about any medical problems or allergies your child has now or has had.</p><p>&nbsp;</p><p>Do not give Singulair Paediatric to your child</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if he/she is allergic to montelukast or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before you give Singulair Paediatric to your child.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If your child&rsquo;s asthma or breathing gets worse, tell your doctor immediately.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Oral Singulair Paediatric is not meant to treat acute asthma attacks. If an attack occurs, follow the instructions your doctor has given you for your child. Always have your child&rsquo;s inhaled rescue medicine for asthma attacks with you.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->It is important that your child take all asthma medications prescribed by your doctor. Singulair Paediatric should not be used instead of other asthma medications your doctor has prescribed for your child.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If your child is on anti-asthma medicines, be aware that if he/she develops a combination of symptoms such as flu-like illness, pins and needles or numbness of arms or legs, worsening of pulmonary symptoms, and/or rash, you should consult your doctor.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Your child should not take acetyl-salicylic acid (aspirin) or anti-inflammatory medicines (also known as non-steroidal anti-inflammatory drugs or NSAIDs) if they make his/her asthma worse.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Do not give this medicine to children less than 2 years of age.</p><p>&nbsp;</p><p>There are different form(s) of this medicine available for paediatric patients under 18 years of age based on age range.</p><p>&nbsp;</p><p>Other medicines and Singulair Paediatric</p><p>Tell your doctor or pharmacist if your child is taking or has recently been given or might be given any other medicines including those obtained without a prescription.</p><p>&nbsp;</p><p>Some medicines may affect how Singulair Paediatric works, or Singulair Paediatric may affect how your child&rsquo;s other medicines work.</p><p>&nbsp;</p><p>Tell your doctor if your child is taking the following medicines before starting Singulair Paediatric:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->phenobarbital (used for treatment of epilepsy)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->phenytoin (used for treatment of epilepsy)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->rifampicin (used to treat tuberculosis and some other infections)</p><p>&nbsp;</p><p>Singulair Paediatric with food and drink</p><p>Singulair Paediatric 4 mg chewable tablets should not be taken immediately with food; they should be taken at least 1 hour before or 2 hours after food.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>This subsection is not applicable for the Singulair Paediatric 4 mg chewable tablets since they are intended for use in children 2 to 5 years of age.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Driving and using machines</p><p>This subsection is not applicable for the Singulair Paediatric 4 mg chewable tablets since they are intended for use in children 2 to 5 years of age, however the following information is relevant to the active ingredient, montelukast.</p><p>&nbsp;</p><p>Singulair Paediatric is not expected to affect your ability to drive a car or operate machinery. However, individual responses to medication may vary. Certain side effects (such as dizziness and drowsiness) that have been reported with Singulair Paediatric may affect some patients&rsquo; ability to drive or operate machinery.</p><p>&nbsp;</p><p>Singulair Paediatric 4 mg chewable tablets contain aspartame, a source of phenylalanine</p><p>If your child has phenylketonuria (a rare, hereditary disorder of the metabolism) you should take into account that each &nbsp;4 mg chewable tablet contains phenylalanine (equivalent to 0.674 mg phenylalanine per 4 mg chewable tablet).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always have your child take this medicine exactly as your doctor or pharmacist has told you. Check with your child&rsquo;s doctor or pharmacist if you are not sure.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->This medicine is to be given to a child under adult supervision. For children who have problems consuming a chewable tablet, an oral granule formulation is available.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Your child should take only one chewable tablet of Singulair Paediatric once a day as</p><p>prescribed by your doctor.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->It should be taken even when your child has no symptoms or if he/she has an acute asthma attack.</p><p>&nbsp;</p><p>For children 2 to 5 years of age:</p><p>The recommended dose is one 4 mg chewable tablet daily to be taken in the evening.</p><p>&nbsp;</p><p>If your child is taking Singulair Paediatric, be sure that he/she does not take any other medicines that contain the same active ingredient, montelukast.</p><p>&nbsp;</p><p>This medicine is for oral use.</p><p>The tablets are to be chewed before swallowing.</p><p>Singulair Paediatric 4 mg chewable tablets should not be taken immediately with food; it should be taken at least 1 hour before or 2 hours after food.</p><p>&nbsp;</p><p>If your child takes more Singulair Paediatric than he/she should</p><p>Contact your child&rsquo;s doctor immediately for advice.</p><p>There were no side effects reported in the majority of overdose reports. The most frequently occurring symptoms reported with overdose in adults and children included abdominal pain, sleepiness, thirst, headache, vomiting, and hyperactivity.</p><p>&nbsp;</p><p>If you forget to give Singulair Paediatric to your child</p><p>Try to give Singulair Paediatric as prescribed. However, if your child misses a dose, just resume the usual schedule of one chewable tablet once daily.</p><p>Do not give a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p>If your child stops taking Singulair Paediatric</p><p>Singulair Paediatric can treat your child&rsquo;s asthma only if he/she continues taking it.</p><p>It is important for your child to continue taking Singulair Paediatric for as long as your doctor prescribes. It will help control your child&rsquo;s asthma.</p><p>If you have any further questions on the use of this medicine, ask your child&rsquo;s doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>In clinical studies with Singulair Paediatric 4 mg chewable tablets, the most commonly reported side effects (occurring in at least 1 of 100 patients and less than 1 of 10 paediatric patients treated) thought to be related to Singulair Paediatric were:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->abdominal pain</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->thirst</p><p>Additionally, the following side effect was reported in clinical studies with Singulair 10 mg film- coated tablets and 5 mg chewable tablets:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->headache</p><p>These were usually mild and occurred at a greater frequency in patients treated with Singulair than placebo (a pill containing no medication).</p><p>&nbsp;</p><p>The frequency of possible side effects listed below is defined using the following convention: Very common: may affect more than 1 in 10 people</p><p>Common: may affect up to 1 in 10 people Uncommon: may affect up to 1 in 100 people Rare: may affect up to 1 in 1,000 people</p><p>Very rare: may affect up to 1 in 10,000 people</p><p>Not known: frequency cannot be estimated from the available data</p><p>&nbsp;</p><p>Additionally, while the medicine has been on the market, the following have been reported:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->upper respiratory infection (<em>Very</em><em> common</em>)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->increased bleeding tendency (<em>Rare</em>)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->allergic reactions including swelling of the face, lips, tongue, and/or throat which may cause difficulty in breathing or swallowing (<em>Uncommon</em>)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->behaviour and mood related changes [dream abnormalities, including nightmares, trouble sleeping, sleep walking, irritability, feeling anxious, restlessness, agitation including aggressive behaviour or hostility, depression (<em>Uncommon</em>); tremor, disturbance in attention, memory impairment (<em>Rare)</em>; hallucinations, disorientation, suicidal thoughts and actions (<em>Very</em><em> rare</em>)]</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->dizziness, drowsiness, pins and needles/numbness, seizure (<em>Uncommon</em>)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->palpitations (<em>Rare</em>)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->nosebleed (<em>Uncommon</em>), swelling (inflammation) of the lungs <em>(Very rare)</em></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->diarrhoea, nausea, vomiting (<em>Common</em>); dry mouth, indigestion (<em>Uncommon</em>)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->hepatitis (inflammation of the liver) (<em>Very</em><em> rare</em>)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->rash <em>(Common)</em>; bruising, itching, hives (<em>Uncommon</em>); tender red lumps under the skin most commonly on your shins (erythema nodosum), severe skin reactions (erythema multiforme) that may occur without warning (<em>Very</em><em> rare</em>)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->joint or muscle pain, muscle cramps (<em>Uncommon</em>)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->fever (<em>Common</em>); weakness/tiredness, feeling unwell, swelling (<em>Uncommon</em>)</p><p>&nbsp;</p><p>In asthmatic patients treated with montelukast, very rare cases of a combination of symptoms such as flu-like illness, pins and needles or numbness of arms and legs, worsening of pulmonary symptoms and/or rash (Churg-Strauss syndrome) have been reported. You must tell your doctor right away if your child gets one or more of these symptoms (See section 2).</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If your child gets any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via &ldquo;The National Pharmacovigilance and Drug Safety Centre (NPC)&rdquo;. By reporting side affects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Keep this medicine out of the sight and reach of children.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Store below 30&deg;C.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Store in the original package in order to protect from light and moisture.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not use this medicine after the expiry date which is stated on the blister after EXP. The first two numbers indicate the month; the last four numbers indicate the year. &nbsp;The expiry date refers to the last date of that month.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Singulair Paediatric contains</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The active substance is montelukast. Each chewable tablet contains montelukast sodium which corresponds to 4 mg of montelukast.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The other ingredients are:</p><p>Mannitol (E 421), microcrystalline cellulose, hyprolose (E 463), red ferric oxide (E 172), croscarmellose sodium, cherry flavour, aspartame (E 951), and magnesium stearate.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Singulair Paediatric looks like and contents of the pack4 mg Singulair Paediatric chewable tablets are pink, oval, biconvex with SINGULAIR engraved on one side and MSD 711 on the other.Blisters in packages of: 7, 10, 14, 20, 28, 30, 50, 56, 98, 100, 140 and 200 tablets. Blisters (unit dose), in packages of: 49x1, 50x1 and 56x1 tablets.Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing</strong><strong> </strong><strong>Authorization</strong><strong> Holder: </strong></p><p>Merck Sharp &amp; Dohme Limited, Hertford Road,</p><p>Hoddesdon, Hertfordshire EN11 9BU,</p><p>UK.</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Merck Sharp &amp; Dohme Limited, Shotton Lane,</p><p>Cramlington, Northumberland, NE23 3JU,</p><p>UK.</p><p>&nbsp;</p><p><strong>Packed by:</strong></p><p>Pharma Pharmaceutical Industries,</p><p>Second Industrial Area,</p><p>P.O. Box 11351 Riyadh, Saudi Arabia</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This package leaflet was last revised on  June 2016Version No. (03)
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>ماهو سينقولير للأطفال</strong></p><p>يُعتبَر سينقولير للأطفال مُضاد مُستقبل لوكترين يُحصر المواد المعروفة باللوكترين.</p><p><strong>كيف يعمل سينقولير للأطفال</strong></p><p>&nbsp;تُسبّب اللوكترين ضيق المجاري التنفسيّة في الرئتَيْن وتورّمها. من خلال إحصار اللوكترين، يُحسّن سينقولير للأطفال عوارض الربو ويُساعد في السيطرة عليها.</p><p><strong>متى يجب استخدام سينقولير للأطفال</strong></p><p>إن هذا الدواء قد تم صرفه خصيصًا لطفلك لمعالجة الربو، ليمنع ظهور أعراض الربو ليلاً ونهارًا.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يُستخدَم سينقولير للأطفال من عمر عامَيْن إلى عمر خمسة أعوام لمعالجة المرضى الذين لا يتحكّمون بمرضهم بشكل ملائم من خلال الأدوية ويحتاجون إلى علاج إضافي.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->قد يُستخدم سينقولير للأطفال كعلاج بديل عن الكورتيكوستيرويدات المستنشقة للمرضى بين عمر عامَيْن وخمسة أعوام الذين لم يتناولوا مؤخّرًا الكورتيكوستيرويدات المستنشقة وتبيّن أنّهم غير قادرين على استخدام الكورتيكوستيرويدات المستنشقة.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->كما يُساهم سينقولير للأطفال في الوقاية من ضيق المجاري التنفسيّة الذي يُسبّبه بذل مجهود عضلي لدى المرضى من عمر عامَيْن وما فوق.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يُستخدَم سينقولير للأطفال لمعالجة الحساسية التي تحدث في الهواء الطلق خلال جزء من السنة (حساسية الأنف الموسمية) لدى الأطفال من عمر عامَيْن إلى عمر خمسة أعوام.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يُستخدَم سينقولير للأطفال لمعالجة الحساسية التي تحدث في الداخل طوال العام (التهاب الأنف التحسسي الدائم) لدى الأطفال من عمر عامَيْن إلى عمر خمسة أعوام.</p><p>سيُحدّد الطبيب طريقة استخدام سينقولير للأطفال كعلاج حسب أعراض الربو لدى طفلك وحدّتها.</p><p><strong>ما هو داء الربو؟</strong></p><p>الربو داء طويل الأمد.</p><p>يشمل الربو:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->صعوبة في التنفّس بسبب ضيق المجاري التنفسيّة. يسوء هذا الضيق ويتحسَّن حسب الظروف المختلفة.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المجاري التنفسيّة الحسّاسة التي تتفاعل مع عدّة عوامل، مثل دخان السيجارة، أو حبوب اللقاح، أو الهواء البارد، أو المجهود العضلي.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التهاب (تورّم) بطانة المجاري التنفسيّة.</p><p>&nbsp;</p><p>تشمل أعراض الربو: السُّعال، والصفير عند التنفّس، وضيق في الصدر.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>اخبر الطبيب على أي حساسيّة أو مشكلة طبيّة لطفلك في الماضي أو في الحاضر.</p><p>&nbsp;</p><p><strong>لا تعطِ طفلك </strong><strong>سينقولير للأطفال إذا كان:</strong></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يُعاني من حساسيّة (أو حساسيّة مفرطة) من مونتيليوكاست أو من أيّ مكوّنات أخرى من سينقولير للأطفال (اقرأ البند 6).</p><p><strong>&nbsp;</strong></p><p><strong>التحذيرات والاحتياطات</strong></p><p><strong>اتصل بالطبيب أو الصيدلي قبل اعطاء طفلك سينقولير للأطفال.</strong></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا ساءت أعراض الربو أو التنفّس لدى طفلك، اتّصل بالطبيب فورًا.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لا يهدف سينقولير للأطفال الفموي إلى معالجة نوبات الربو الحادّة. في حال حدوث نوبة، يُرجى اتّباع تعليمات الطبيب لطفلك. يجب أن يُلازمك جهاز الاستنشاق الانقاذي دائمًا في حال تعرّض طفلك لنوبات ربو.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->من الضروري أن يتناول طفلك أدوية الربو كلّها التي وصفها طبيبك. يجب عدم استخدام سينقولير للأطفال بدلًا عن أدوية ربو أخرى وصفها الطبيب لطفلك.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->على طفلك الذي يتناول أدوية مُضادة للربو أن يُدرك أنّه في حال تطوّرت مجموعة أعراض، مثل أعراض الرشح، أو الوخزات أو التنميل في الذراعَيْن والساقَيْن، وتدهور حال الأعراض الرئويّة، و/أو الطفح الجلدي، يجب استشارة الطبيب.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يجب عدم تناول حَمْض الأستيل سلسيليك (الأسبرين) أو الأدوية المُضادة للالتهابات (المعروفة أيضًا بالأدوية المُضادة للالتهابات اللاستيرويديّة) في حال كانت تزيد من أعراض الربو لدى طفلك.</p><p><strong>الأطفال والمراهقين</strong></p><p>لا تعطِ الدواء للأطفال أقل من عمر سنتين.</p><p>هناك أشكال صيدلانية مختلفة لهذا الدواء للمرضى الأطفال تحت عمر 18 سنة على أساس الفئة العمرية</p><p><strong>تناول أدوية أخرى مع سينقولير للأطفال</strong></p><p>يُرجى إطلاع الطبيب أو الصيدلي في حال كان طفلك يتناول، في الماضي أو في الحاضر، أدوية أخرى، بما في ذلك تلك الأدوية من دون وصفة طبيّة.</p><p>قد تؤثّر بعض الأدوية على مفعول سينقولير للأطفال وقد يؤثّر سينقولير للأطفال على مفعول أدوية أخرى.</p><p>اخبر الطبيب إذا كان طفلك يتناول الأدوية التالية قبل البدء بتناول سينقولير للأطفال:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فينوباربيتال (المستخدَم لمعالجة داء الصَّرع)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فينيتوين (المستخدَم لمعالجة داء الصَّرع)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ريفامبيسين (المستخدَم لمعالجة داء السّلّ وبعض الالتهابات الأخرى)</p><p><strong>تناول سينقولير للأطفال مع الطعام أو الشراب</strong></p><p>يجب عدم تناول أقراص سينقولير للأطفال 4 ملغم القابلة للمضغ مباشرةً مع الطعام؛ بل يجب تناولها قبل ساعة على الأقل من تناول الطعام أو بعد ساعتَيْن من تناول الطعام.</p><p><strong>الحمل والرضاعة</strong></p><p>لا ينطبق هذا القسم الفرعي على أقراص سينقولير للأطفال 4 ملغم القابلة للمضغ بما أنّها موجّهة للأطفال بين عمر عامَيْن وخمسة أعوام.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>القيادة واستخدام الآليّات</strong></p><p>لا ينطبق هذا القسم الفرعي على أقراص سينقولير للأطفال 4 ملغم القابلة للمضغ بما أنّها موجّهة للأطفال بين عمر عامَيْن وخمسة أعوام. لكنّ المعلومات التالية مرتبطة بالمادة الفاعلة، المونتيليوكاست.</p><p>لا يُتوقَّع أن يؤثّر سينقولير على قدرتك على القيادة أو على تشغيل الآليّات. لكن، قد تختلف الردود الفرديّة على الأدوية. قد تؤثّر بعض الآثار الجانبيّة (مثل الدوخة والنُعاس) التي تمّ الابلاغ عنها بشكل نادرٍ جدًّا مع سينقولير على قدرة بعض المرضى على القيادة أو تشغيل الآليّات.</p><p><strong>&nbsp;</strong></p><p><strong>أقراص </strong><strong>سينقولير للأطفال القابلة للمضغ تحتوي على الأسبارتام، وهو مصدر للفينيلالانين</strong></p><p>&nbsp;في حال كان طفلك مُصابًا ببيلة الفيلين كيتون (وهو اضطراب أيضي وراثي ونادر)، عليك أن تأخذ بعين الاعتبار أن كل قرص 4 ملغم قابلاً للمضغ يحتوي على الفينيلالانين (ما يُساوي 0.674 ملغ من الفينيلالانين لكل قرص 4 ملغم القابل للمضغ).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>على طفلك تناول سينقولير للأطفال دائمًا بناءً على وصفة الطبيب. عليك مراجعة الطبيب أو الصيدلي في حال لم تكن متأكّدًا</p><p>- يُعطى هذا الدواء إلى الطفل تحت إشراف بالغين. بالنسبة للأطفال ممن يصعب عليهم تناول القرص القابل للمضغ، فإن العقار متوفر على شكل حبيبات للتناول عن طريق الفم.</p><p>- على طفلك تناول قرص واحد فقط من سينقولير للأطفال مرةً واحدةً في اليوم حسب وصفة الطبيب.</p><p>- يجب تناول الدواء وإن لم يكن طفلك يعاني من أي أعراض أو إن حصلت له نوبة ربو حادّة.</p><p>&nbsp;</p><p><strong>بالنسبة للأطفال من بين عمر عامَيْن إلى 5 أعوام</strong></p><p>يؤخذ قرصًا واحدًا 4 ملغم القابل للمضغ يوميًّا مساءً.</p><p>&nbsp;إذا كان طفلك يتناول سينقولير للأطفال، احرص على ألا يتناول أي أدوية أخرى قد تحتوي على المادة الفعّالة نفسها، مونتيليوكاست.</p><p>هذا الدواء للتناول عن طريق الفم.</p><p>يجب مضغ الأقراص قبل بلعها.</p><p>&nbsp;يجب عدم تناول أقراص سينقولير للأطفال 4 ملغم القابلة للمضغ مباشرةً مع الطعام، يجب تناولها قبل ساعة من تناول الطعام أو بعد مرور ساعتَيْن على تناول الطعام.</p><p>&nbsp;</p><p><strong>في حال تناول طفلك جرعة زائدة من سينقولير للأطفال</strong></p><p>عليك الاتصال فورًا بالطبيب للحصول على مشورته.</p><p>لم يتم الإبلاغ عن أعراض جانبيّة في غالبيّة تقارير الجرعة الزائدة. تشمل الأعراض الأكثر شيوعًا التي تم الإبلاغ عنها للجرعة الزائدة لدى الكبار والأطفال ألمًا في البطن، والنُعاس، والعطش، والصداع، والتقيؤ، والنشاط المُفرَط.</p><p>&nbsp;</p><p><strong>في حال نسيت إعطاء سينقولير للأطفال لطفلك</strong></p><p>حاول إعطاء سينقولير للأطفال بحسب الوصفة. لكن، في حال فوّت طفلك جرعةً، استأنف الجدول الزمني المُعتاد على أساس قرص واحد يوميًّا.</p><p>لا تُعطِ جرعةً مضاعفةً للتعويض عن الجرعة المنسيّة.</p><p>&nbsp;</p><p><strong>في حال توقّف طفلك عن تناول سينقولير للأطفال</strong></p><p>لا يُمكن لسينقولير للأطفال معالجة داء الربو لدى طفلك إلّا في حال تابع طفلك تناوله.</p><p>من الضروري مواصلة طفلك تناول سينقولير للأطفال للمدّة التي وصفها الطبيب له. سيُساعدك ذلك في السيطرة على داء الربو لدى طفلك.</p><p>في حال كان لديك أسئلة إضافيّة حول استخدام هذا المُنتَج، اتّصل بالطبيب أو بالصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>على غرار الأدوية كلّها، يُمكن أن يُسبّب سينقولير للأطفال أعراضًا جانبيةً وإن كانت لا تُصيب الجميع.</p><p>&nbsp;</p><p>في الدراسات السريريّة على أقراص سينقولير للأطفال 4 ملغم القابلة للمضغ، الأعراض الجانبيّة التي تم الإبلاغ عنها الأكثر شيوعًا (التي تحدث لدى 1 من أصل 100 مريض على الأقل ولدى أقلّ من 1 من أصل 10 مرضى أطفال مُعالجين) التي يُعتقد بأنّها مرتبطة بسينقولير للأطفال هي:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم في البطن</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->العطش</p><p>بالإضافة إلى ذلك، تمّ الإبلاغ عن العرض الجانبي التالي في الدراسات السريريّة حول أقراص سينقولير 10 ملغم المغلّفة والأقراص 5 ملغم القابلة للمضغ:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->صُداع</p><p>كانت هذه الأعراض بالأغلب معتدلة، تكرّرت بوتيرة أعلى لدى المرضى المُعالجين بسينقولير، مقارنةً بقرص العلاج الذي لا يحتوي على المادة الفعالة.</p><p>&nbsp;</p><p>يتمّ تحديد وتيرة الأعراض الجانبيّة المحتملة المدرجة أدناه وفق التعريفات التالية:</p><p>شائعة جدًا (تؤثّر على &nbsp;أكثر من واحد من أصل 10 مرضى)</p><p>شائعة (تؤثّر على واحد من أصل &nbsp;10 مرضى)</p><p>غير شائعة (تؤثّر على واحد من أصل100 مريض)</p><p>نادرة (تؤثّر على واحد من أصل 1000 مريض)</p><p>نادرة جدًّا (تؤثّر على واحد من أصل 10000 مريض)</p><p>غير معروفة: لا يُمكن تقدير تكرارها إنطلاقًا من البيانات المتوفّرة</p><p>&nbsp;</p><p>بالإضافة إلى ذلك، تمّ الابلاغ عن الأعراض الجانبيّة التالية بينما كان الدواء مطروحًا في السوق:</p><p>- التهاب الجهاز التنفسي العلوي (<em>شائعة جدًا</em>)</p><p>- زيادة احتمالية النزف (<em>نادرة</em>)</p><p>- ردود الفعل الحساسيّة، بما في ذلك تورّم الوجه، والشفتَيْن، واللسان، و/أو الحنجرة التي قد تُسبّب صعوبةً في التنفّس أو البلع (<em>غير شائعة</em>)</p><p>- تبدّل السلوك والتغيّرات المزاجيّة (الأحلام غير الاعتياديّة، بما في ذلك الكوابيس، واضطرابات النوم، والمشي أثناء النوم والإنزعاج، والشعور بالتوتّر، والأرق، والاضطراب، بما في ذلك السلوك العدائي أو العداوة، والاكتئاب (<em>غير شائعة</em>)؛ والرُعاش، والخلل في التركيز، والخلل في الذاكرة (<em>نادرةً</em>)؛ والهلوسات، والارتباك، والأفعال والأفكار الانتحاريّة (<em>نادرة جدًّا</em>)؛</p><p>- الدوار، والنُعاس، والوخزات والابر/التنميل، والتشنجات (<em>غير شائعة</em>)؛</p><p>- خفقان القلب (<em>نادرةً</em>)؛</p><p>- نزيف الأنف (<em>غير شائعة</em>)، تورم (التهاب) الرئتَيْن (<em>نادرة جدًّا</em>)؛</p><p>- الاسهال، الغثيان، التقيّؤ (<em>شائعة</em>)؛ جفاف الفم، عُسر الهضم (<em>غير شائعة</em>)؛</p><p>- التهاب الكبد (<em>نادرة جدًّا</em>)؛</p><p>- الطفح الجلدي (<em>شائعة</em>)؛ التّكدم، &nbsp;الحكة، الشرى (<em>غير شائعة</em>)؛ حمامى عقدة (عُقَد حمراء &nbsp;تحت الجلد مؤلمة، تكون في غالبيّة الحالات على الساق)، ردود فعل جلديّة حادّة (حُمامى عديدة الأشكال) قد تطرأ من دون سابق إنذار (<em>نادرة جدًّا</em>)؛</p><p>- ألم في المفاصل أو في العضلات، تشنّجات عضليّة (<em>غير شائعة</em>)؛</p><p>- حمى (<em>شائعة</em>)؛ وهن/تعب، شعور بالانزعاج، تورّم (<em>غير شائعة</em>).</p><p>لدى المرضى المُصابين بالربو والمُعالجين بالمونتيليوكاست، تمّ الابلاغ عن حالات نادرة جدًّا من مجموعة أعراض، مثل أعراض الرشح والوخزات/التنميل في الذراعَيْن والساقَيْن، وازدياد الأعراض الرئويّة سوءًا و/أو الطفح الجلدي (متلازمة شيرغ &ndash; ستراوس). عليك إطلاع طبيبك مباشرةً في حال تعرّض طفلك لأحد هذه الأعراض أو أكثر (انظر البند2).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>الإبلاغ عن الأعراض الجانبيّة</strong></p><p>في حال تعرّض طفلك لأعراض جانبيّة، يُرجى التحدّث إلى الطبيب، أو الصيدلي، أو الممرّضة. يشمل ذلك أي أعراض جانبيّة مُحتملة غير مُدرجة في هذه اللائحة. يمكنك الإبلاغ عن الأعراض الجانبية عن طريق &quot;المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء&quot; . من خلال الإبلاغ عن الآثار الجانبيّة، يساهم ذلك في إعطاء المزيد من المعلومات عن سلامة هذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يُحفظ بعيدًا عن متناول أيدي ومرأى الأطفال.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يُحفظ في درجة حرارة أقل من ٣۰ درجة مئوية.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يُحفظ في العبوة الأصلية لحمايته من الضوء و الرطوبة.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لا تستخدم هذا الدواء بعد انقضاء التاريخ الوارد من خلال الستة أرقام التي تلي EXP على الشريط. يُشير الرقمان الأولان إلى &nbsp;الشهر، &nbsp;والاربع أرقام الأخيرة إلى السنة. تنتهي صلاحيّة الدواء في نهاية الشهر المذكور.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يجب عدم التخلّص من الأدوية عبر النفايات المنزليّة أو مياه الصرف الصحي. يُرجى مراجعة الصيدلي لمعرفة كيفيّة التخلّص من الأدوية غير المستعملة. ومن شأن هذه الإجراءات أن تُساهم في حماية البيئة.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><!--[if !supportLists]--><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>محتويات العبوة ومعلومات أخرى</strong></p><p><strong>محتوى سينقولير للأطفال</strong></p><p>- المادة الفعالة هي مونتيليوكاست. يحتوي كل قرص على صوديوم مونتيليوكاست الذي يُعادل 4 ملغم مونتيليوكاست.</p><p>- المكوّنات الأخرى هي: مانيتول (E 421)، وسليولوز دقيق التبلور، هيبرولوز (E 463)، وأكسيد الحديد الأحمر (E 172)، وكروسكارميلوز صوديوم، نكهة الكرز،و أسبارتام (E 951) ،و ستيارات المغنسيوم.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            أشكال سينقولير للأطفال ومحتوى العلبةأقراص سينقولير للأطفال 4 ملغم القابلة للمضغ زهريّة اللون، بيضاوية الشكل، ومقوّسة الوجهَيْن، مع كلمة سينقولير SINGULAIR محفورة عليها من جهة 711 MSD على الجهة الأخرى.الأشرطة في عبوات من: 7، و10، 14، و20، و28، و30، و50، و56، و98، و100، و140، و200 قرص.الأشرطة (الجرعات الفرديّة) في عبوات من 49x1، و50x1، و56x1 قرصًا.قد لا يتم تسويق جميع أحجام العبوات
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الشركة المالكة لحقوق التسويق: </strong></p><p>ميرك شارب ودوم المحدودة،</p><p>طريق هيرتفورد، هوديسدون، هيرتفوردشاير</p><p>&nbsp;أي أن ١١ ٩ بي يو، المملكة المتحدة</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>الشركة </strong><strong>الصانعة</strong><strong>:</strong></p><p>ميرك شارب ودوم ليميتد، شوتون لين،</p><p>كراملينجتون، نورثمبرلاند، إن إي ٣٣٢جي يو،</p><p>المملكة المتحدة</p><p>&nbsp;</p><p><strong>التغليف بواسطة:</strong></p><p>فارما للصناعات الدوائية<br />المنطقة الصناعية الثانية،<br />ص ب: 11351 الرياض، المملكة العربية السعودية</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمّت آخر مراجعة لهذة النشرة بتاريخ حزيران/يونيو 2016الإصدار رقم (3)
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Singulair® Paediatric 4 mg chewable Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One chewable tablet contains montelukast sodium, which is equivalent to 4 mg montelukast.

Excipient with known effect: This medicine contains 1.2 mg aspartame (E 951) per tablet.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Chewable tablet.

Pink, oval, bi-convex-shaped, SINGULAIR engraved on one side and MSD 711 on the other.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><!--[if !supportLists]-->1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Therapeutic indications</p><p><strong>&nbsp;</strong></p><p>Singulair Paediatric is indicated in the treatment of asthma as add-on therapy in those 2 to 5 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom &ldquo;as-needed&rdquo; short-acting b-agonists provide inadequate clinical control of asthma.</p><p>&nbsp;</p><p>Singulair Paediatric may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to 5 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.2).</p><p>&nbsp;</p><p>Singulair Paediatric is also indicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction.</p><p>Singulair Paediatric is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 to 5 years of age and perennial allergic rhinitis in patients 2 to 5 years of age.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>This medicinal product is to be given to a child under adult supervision. For children who have problems consuming a chewable tablet, a granule formulation is available (see Singulair Paediatric 4 mg Granules SmPC). The recommended dose for paediatric patients 2-5 years of age is one 4 mg chewable tablet daily to be taken in the</p><p>&nbsp;</p><p>evening.&nbsp; &nbsp;If taken in connection with food, Singulair should be taken 1 hour before or 2 hours after food. No dosage adjustment within this age group is necessary.</p><p>&nbsp;</p><p><u>General recommendations</u></p><p>The therapeutic effect of Singulair on parameters of asthma control occurs within one day. Patients should be advised to continue taking Singulair even if their asthma is under control, as well as during periods of worsening asthma.</p><p>&nbsp;</p><p>No dosage adjustment is necessary for patients with renal insufficiency, or mild to moderate hepatic impairment. There are no data on patients with severe hepatic impairment. The dosage is the same for both male and female patients.</p><p>&nbsp;</p><p><u>Singulair as an alternative treatment option to low-dose inhaled corticosteroids for</u> &nbsp;<u>mild, persistent asthma</u></p><p>Montelukast is not recommended as monotherapy in patients with moderate persistent asthma. The use of montelukast as an alternative treatment option to low-dose inhaled corticosteroids for children with mild persistent asthma should only be considered for patients who do not have a recent history of serious asthma attacks that required oral corticosteroid use and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.1). Mild persistent asthma is defined as asthma symptoms more than once a week but less than once a day, nocturnal symptoms more than twice a month but less than once a week, normal lung function between episodes. If satisfactory control of asthma is not achieved at follow-up (usually within one month), the need for an additional or different anti-inflammatory therapy based on the step system for asthma therapy should be evaluated. Patients should be periodically evaluated for their asthma control.</p><p>&nbsp;</p><p><u>Singulair as prophylaxis of asthma for 2 to 5 year old patients in whom the</u> &nbsp;<u>predominant component is exercise-induced bronchoconstriction</u></p><p>In 2 to 5 year old patients, exercise-induced bronchoconstriction may be the predominant manifestation of persistent asthma that requires treatment with inhaled corticosteroids. Patients should be evaluated after 2 to 4 weeks of treatment with montelukast. If satisfactory response is not achieved, an additional or different therapy should be considered.</p><p>&nbsp;</p><p><u>Therapy with Singulair in relation to other treatments for asthma</u></p><p>When treatment with Singulair is used as add-on therapy to inhaled corticosteroids, Singulair should not be abruptly substituted for inhaled corticosteroids (see section 4.4).</p><p>&nbsp;</p><p>10 mg film-coated tablets are available for adults and adolescents 15 years of age and older.</p><p>&nbsp;</p><p><em>Paediatric</em><em> </em><em>population</em></p><p>Do not give Singulair 4 mg chewable tablets to children less than 2 years of age. The safety and efficacy of Singulair 4 mg chewable tablets in children less than 2 years of age has not been established.</p><p>&nbsp;</p><p>5 mg chewable tablets are available for paediatric patients 6 to 14 years of age. 4 mg granules are available for paediatric patients 6 months to 5 years of age.</p><p>&nbsp;</p><p><u>Method of administration</u> Oral use.</p><p>The tablets are to be chewed before swallowing.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised never to use oral montelukast to treat acute asthma attacks and to keep their usual appropriate rescue medication for this purpose readily available. If an acute attack occurs, a short-acting inhaled b-agonist should be used. Patients should seek their doctors&rsquo; advice as soon as possible if they need more inhalations of short-acting b-agonists than usual.</p><p>&nbsp;</p><p>Montelukast should not be abruptly substituted for inhaled or oral corticosteroids.</p><p>&nbsp;</p><p>There are no data demonstrating that oral corticosteroids can be reduced when montelukast is given concomitantly.</p><p>&nbsp;</p><p>In rare cases, patients on therapy with anti-asthma agents including montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These cases have been sometimes associated with the reduction or withdrawal of oral corticosteroid therapy. Although a causal relationship with leukotriene receptor antagonism has not been established, physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. Patients who develop these symptoms should be reassessed and their treatment regimens evaluated.</p><p>&nbsp;</p><p>Treatment with montelukast does not alter the need for patients with aspirin-sensitive asthma to avoid taking aspirin and other non-steroidal anti-inflammatory drugs.</p><p>&nbsp;</p><p>Singulair contains aspartame, a source of phenylalanine. Patients with phenylketonuria should take into account that each 4 mg chewable tablet contains phenylalanine in an amount equivalent to 0.674 mg phenylalanine per dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medicinal products: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl oestradiol/norethindrone 35/1), terfenadine, digoxin and warfarin.</p><p>&nbsp;</p><p>The area under the plasma concentration curve (AUC) for montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. Since montelukast is metabolised by CYP 3A4, 2C8, and 2C9, caution should be exercised, particularly in children, when montelukast is co-administered with inducers of CYP 3A4, 2C8, and 2C9, such as phenytoin, phenobarbital and rifampicin.</p><p>&nbsp;</p><p><em>In vitro </em>studies have&nbsp; shown that montelukast is a&nbsp; potent inhibitor of CYP 2C8. However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of medicinal products primarily metabolised by CYP 2C8) demonstrated that montelukast does not inhibit CYP 2C8 <em>in vivo. </em>Therefore, montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolised by this enzyme (eg., paclitaxel, rosiglitazone, and repaglinide).</p><p>&nbsp;</p><p><em>In vitro </em>studies have shown that montelukast is a substrate of CYP 2C8, and to a less significant extent, of 2C9, and 3A4. In a clinical drug-drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) gemfibrozil increased the systemic exposure of montelukast by 4.4-fold. No routine dosage adjustment of montelukast is required upon co-administration with gemfibrozil or other potent inhibitors of CYP 2C8, but the physician should be aware of the potential for an increase in adverse reactions.</p><p>&nbsp;</p><p>Based on <em>in vitro </em>data, clinically important drug interactions with less potent inhibitors of CYP 2C8 (e.g., trimethoprim) are not anticipated. Co-administration of montelukast with itraconazole, a strong inhibitor of CYP 3A4, resulted in no significant increase in the systemic exposure of montelukast.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Animal studies do not indicate harmful effects with respect to effects on pregnancy or embryonal/foetal development.</p><p>&nbsp;</p><p>Limited data from available pregnancy databases do not suggest a causal relationship between Singulair and malformations (i.e. limb defects) that have been rarely reported in worldwide post-marketing experience.</p><p>Singulair may be used during pregnancy only if it is considered to be clearly essential. <u>Breast-feeding</u></p><p>Studies in rats have shown that montelukast is excreted in milk (see section 5.3). It is unknown whether montelukast/metabolites are excreted in human milk.</p><p>&nbsp;</p><p>Singulair may be used in breast-feeding mothers only if it is considered to be clearly essential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Singulair has no or negligible influence on the ability to drive and use machines. However, individuals have reported drowsiness or dizziness.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast has been evaluated in clinical studies in patients with persistent asthma as follows:</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->10 mg film-coated tablets in approximately 4,000 adult and adolescent patients 15 years of age and older</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->5 mg chewable tablets in approximately 1,750 paediatric patients 6 to 14 years of age, and</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->4 mg chewable tablets in 851 paediatric patients 2 to 5 years of age.</p><p>Montelukast has been evaluated in a clinical study in patients with intermittent asthma as follows:</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->4 mg granules and chewable tablets in 1,038 paediatric patients 6 months to 5 years of age</p><p>&nbsp;</p><p>The following drug-related adverse reactions in clinical studies were reported commonly (&ge;1/100 to &lt;1/10) in patients treated with montelukast and at a greater incidence than in patients treated with placebo:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:109.1pt; vertical-align:top; width:106.3pt"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Body System Class</strong></p></td><td style="border-color:black; height:109.1pt; vertical-align:top; width:99.25pt"><p>&nbsp;</p><p><strong>Adult</strong><strong> </strong><strong>and Adolescent Patients 15 years and older</strong></p><p><strong>(two</strong><strong> </strong><strong>12-week</strong><strong> </strong><strong>studies;</strong><strong> </strong><strong>n=795)</strong></p></td><td style="border-color:black; height:109.1pt; vertical-align:top; width:106.3pt"><p><strong>Paediatric</strong><strong> </strong><strong>Patients</strong><strong> </strong><strong>6 to 14 years old (one 8-week</strong></p><p><strong>study;</strong><strong> </strong><strong>n=201)</strong></p><p>&nbsp;</p><p><strong>(two</strong><strong> </strong><strong>56 week studies; n=615)</strong></p></td><td style="border-color:black; height:109.1pt; vertical-align:top; width:106.3pt"><p><strong>Paediatric</strong><strong> </strong><strong>Patients</strong><strong> </strong><strong>2 to 5 years old (one 12-week study; n=461)</strong></p><p>&nbsp;</p><p><strong>(one</strong><strong> </strong><strong>48-week</strong><strong> </strong><strong>study;</strong><strong> </strong><strong>n=278)</strong></p></td></tr><tr><td style="border-color:black; height:40.1pt; vertical-align:top; width:106.3pt"><p><strong>Nervous</strong><strong> </strong><strong>system disorders</strong></p></td><td style="height:40.1pt; vertical-align:top; width:99.25pt"><p>&nbsp;</p><p>headache</p></td><td style="height:40.1pt; vertical-align:top; width:106.3pt"><p>&nbsp;</p><p>headache</p></td><td style="height:40.1pt; vertical-align:top; width:106.3pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:40.1pt; vertical-align:top; width:106.3pt"><p><strong>Gastro-intestinal</strong><strong> </strong><strong>disorders</strong></p></td><td style="height:40.1pt; vertical-align:top; width:99.25pt"><p>&nbsp;</p><p>abdominal pain</p></td><td style="height:40.1pt; vertical-align:top; width:106.3pt"><p>&nbsp;</p></td><td style="height:40.1pt; vertical-align:top; width:106.3pt"><p>&nbsp;</p><p>abdominal pain</p></td></tr><tr><td style="border-color:black; height:53.9pt; vertical-align:top; width:106.3pt"><p><strong>General</strong><strong> </strong><strong>disorders</strong><strong> </strong><strong>and administration site conditions</strong></p></td><td style="height:53.9pt; vertical-align:top; width:99.25pt"><p>&nbsp;</p></td><td style="height:53.9pt; vertical-align:top; width:106.3pt"><p>&nbsp;</p></td><td style="height:53.9pt; vertical-align:top; width:106.3pt"><p>&nbsp;</p><p>thirst</p></td></tr></tbody></table><p>&nbsp;</p><p>With prolonged treatment in clinical trials with a limited number of patients for up to 2 years for adults, and up to 12 months for paediatric patients 6 to 14 years of age, the safety profile did not change.</p><p>&nbsp;</p><p>Cumulatively, 502 paediatric patients 2 to 5 years of age were treated with montelukast for at least 3 months, 338 for 6 months or longer, and 534 patients for 12 months or longer. With prolonged treatment, the safety profile did not change in these patients either.</p><p>&nbsp;</p><p><u>Tabulated</u><u> </u><u>list</u><u> </u><u>of Adverse Reactions</u></p><p>&nbsp;</p><p>Adverse reactions reported in post-marketing use are listed, by System Organ Class and specific Adverse Reactions, in the table below. Frequency Categories were estimated based on relevant clinical trials.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:29.3pt; vertical-align:top; width:150.0pt"><p><strong>System Organ Class</strong></p></td><td style="border-color:black; height:29.3pt; vertical-align:top; width:147.0pt"><p><strong>Adverse</strong><strong> </strong><strong>Reactions</strong></p></td><td style="border-color:black; height:29.3pt; vertical-align:top; width:117.0pt"><p><strong>Frequency</strong><strong> </strong><strong>Category*</strong></p></td></tr><tr><td style="border-color:black; height:15.25pt; vertical-align:top; width:150.0pt"><p>Infections and infestations</p></td><td style="height:15.25pt; vertical-align:top; width:147.0pt"><p>upper respiratory infection&dagger;</p></td><td style="height:15.25pt; vertical-align:top; width:117.0pt"><p>Very Common</p></td></tr><tr><td style="border-color:black; height:29.15pt; vertical-align:top; width:150.0pt"><p>Blood and lymphatic system disorders</p></td><td style="height:29.15pt; vertical-align:top; width:147.0pt"><p>increased bleeding tendency</p></td><td style="height:29.15pt; vertical-align:top; width:117.0pt"><p>Rare</p></td></tr><tr><td style="border-color:black; height:29.05pt; vertical-align:top; width:150.0pt" rowspan="2"><p>Immune system disorders</p></td><td style="height:29.05pt; vertical-align:top; width:147.0pt"><p>hypersensitivity reactions including anaphylaxis</p></td><td style="height:29.05pt; vertical-align:top; width:117.0pt"><p>Uncommon</p></td></tr><tr><td style="height:28.2pt; vertical-align:top; width:147.0pt"><p>hepatic eosinophilic infiltration</p></td><td style="height:28.2pt; vertical-align:top; width:117.0pt"><p>Very Rare</p></td></tr><tr><td style="border-color:black; height:125.65pt; vertical-align:top; width:150.0pt" rowspan="3"><p>Psychiatric disorders</p></td><td style="height:125.65pt; vertical-align:top; width:147.0pt"><p>dream abnormalities including nightmares, insomnia, somnambulism, anxiety, agitation including aggressive behaviour or hostility, depression, psychomotor hyperactivity (including irritability,</p><p>restlessness, tremor&sect;)</p></td><td style="height:125.65pt; vertical-align:top; width:117.0pt"><p>Uncommon</p></td></tr><tr><td style="height:28.1pt; vertical-align:top; width:147.0pt"><p>disturbance in attention, memory impairment</p></td><td style="height:28.1pt; vertical-align:top; width:117.0pt"><p>Rare</p></td></tr><tr><td style="height:55.7pt; vertical-align:top; width:147.0pt"><p>hallucinations, disorientation, suicidal thinking and behaviour (suicidality)</p></td><td style="height:55.7pt; vertical-align:top; width:117.0pt"><p>Very Rare</p></td></tr><tr><td style="border-color:black; height:42.95pt; vertical-align:top; width:150.0pt"><p>Nervous system disorders</p></td><td style="height:42.95pt; vertical-align:top; width:147.0pt"><p>dizziness, drowsiness, paraesthesia/hypoesthesia, seizure</p></td><td style="height:42.95pt; vertical-align:top; width:117.0pt"><p>Uncommon</p></td></tr><tr><td style="border-color:black; height:15.25pt; vertical-align:top; width:150.0pt"><p>Cardiac disorders</p></td><td style="height:15.25pt; vertical-align:top; width:147.0pt"><p>palpitations</p></td><td style="height:15.25pt; vertical-align:top; width:117.0pt"><p>Rare</p></td></tr><tr><td style="border-color:black; height:15.35pt; vertical-align:top; width:150.0pt" rowspan="3"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="height:15.35pt; vertical-align:top; width:147.0pt"><p>epistaxis</p></td><td style="height:15.35pt; vertical-align:top; width:117.0pt"><p>Uncommon</p></td></tr><tr><td style="height:28.1pt; vertical-align:top; width:147.0pt"><p>Churg-Strauss Syndrome (CSS) (see section 4.4)</p></td><td style="height:28.1pt; vertical-align:top; width:117.0pt"><p>Very Rare</p></td></tr><tr><td style="height:14.3pt; vertical-align:top; width:147.0pt"><p>pulmonary eosinophilia</p></td><td style="height:14.3pt; vertical-align:top; width:117.0pt"><p>Very Rare</p></td></tr><tr><td style="border-color:black; height:29.15pt; vertical-align:top; width:150.0pt" rowspan="2"><p>Gastrointestinal disorders</p></td><td style="height:29.15pt; vertical-align:top; width:147.0pt"><p>diarrhoea&Dagger;, nausea&Dagger;, vomiting&Dagger;</p></td><td style="height:29.15pt; vertical-align:top; width:117.0pt"><p>Common</p></td></tr><tr><td style="height:14.3pt; vertical-align:top; width:147.0pt"><p>dry mouth, dyspepsia</p></td><td style="height:14.3pt; vertical-align:top; width:117.0pt"><p>Uncommon</p></td></tr><tr><td style="border-color:black; height:29.05pt; vertical-align:top; width:150.0pt" rowspan="2"><p>Hepatobiliary disorders</p></td><td style="height:29.05pt; vertical-align:top; width:147.0pt"><p>elevated levels of serum transaminases (ALT, AST)</p></td><td style="height:29.05pt; vertical-align:top; width:117.0pt"><p>Common</p></td></tr><tr><td style="height:55.7pt; vertical-align:top; width:147.0pt"><p>hepatitis (including cholestatic, hepatocellular, and mixed-pattern liver injury).</p></td><td style="height:55.7pt; vertical-align:top; width:117.0pt"><p>Very Rare</p></td></tr><tr><td style="border-color:black; height:15.35pt; vertical-align:top; width:150.0pt" rowspan="4"><p>Skin and subcutaneous tissue disorders</p></td><td style="height:15.35pt; vertical-align:top; width:147.0pt"><p>rash&Dagger;</p></td><td style="height:15.35pt; vertical-align:top; width:117.0pt"><p>Common</p></td></tr><tr><td style="height:14.3pt; vertical-align:top; width:147.0pt"><p>bruising, urticaria, pruritus</p></td><td style="height:14.3pt; vertical-align:top; width:117.0pt"><p>Uncommon</p></td></tr><tr><td style="height:14.3pt; vertical-align:top; width:147.0pt"><p>angiooedema</p></td><td style="height:14.3pt; vertical-align:top; width:117.0pt"><p>Rare</p></td></tr><tr><td style="height:28.1pt; vertical-align:top; width:147.0pt"><p>erythema nodosum, erythema multiforme</p></td><td style="height:28.1pt; vertical-align:top; width:117.0pt"><p>Very Rare</p></td></tr><tr><td style="border-color:black; height:29.15pt; vertical-align:top; width:150.0pt"><p>Musculoskeletal and connective tissue disorders</p></td><td style="height:29.15pt; vertical-align:top; width:147.0pt"><p>arthralgia, myalgia including muscle cramps</p></td><td style="height:29.15pt; vertical-align:top; width:117.0pt"><p>Uncommon</p></td></tr><tr><td style="border-color:black; height:15.25pt; vertical-align:top; width:150.0pt"><p>General disorders and</p></td><td style="height:15.25pt; vertical-align:top; width:147.0pt"><p>pyrexia&Dagger;</p></td><td style="height:15.25pt; vertical-align:top; width:117.0pt"><p>Common</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:28.1pt; vertical-align:top; width:150.0pt"><p>administration site conditions</p></td><td style="border-color:black; height:28.1pt; vertical-align:top; width:147.0pt"><p>asthenia/fatigue, malaise, oedema</p></td><td style="border-color:black; height:28.1pt; vertical-align:top; width:117.0pt"><p>Uncommon</p></td></tr><tr><td style="border-color:black; height:101.3pt; vertical-align:top; width:5.75in" colspan="3"><p>&nbsp;</p><p>*Frequency Category: Defined for each Adverse Reaction by the incidence reported in the clinical trials data base: Very Common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very Rare (&lt;1/10,000).</p><p>&dagger;This adverse experience, reported as Very Common in the patients who received montelukast, was also reported as Very Common in the patients who received placebo in clinical trials.</p><p>&Dagger;This adverse experience, reported as Common in the patients who received montelukast, was also reported as</p><p>Common in the patients who received placebo in clinical trials.</p><p>&sect; Frequency Category: Rare</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To report any side effect(s):</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Saudi Arabia: </u></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In chronic asthma studies, montelukast &nbsp;has &nbsp;been &nbsp;administered &nbsp;at &nbsp;doses &nbsp;up &nbsp;to 200 mg/day to adult patients for 22 weeks and in short-term studies, up to 900 mg/day to patients for approximately one week without clinically important adverse experiences.</p><p>&nbsp;</p><p>There have been reports of acute overdose in post-marketing experience and clinical studies with montelukast. These include reports in adults and children with a dose as high as 1,000 mg (approximately 61 mg/kg in a 42 month old child). The clinical and laboratory findings observed were consistent with the safety profile in adults and paediatric patients. There were no adverse experiences in the majority of overdose reports.</p><p>&nbsp;</p><p><u>Symptoms of overdose</u></p><p>The most frequently occurring adverse experiences were consistent with the safety profile of montelukast and included abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity.</p><p>&nbsp;</p><p><u>Management of overdose</u></p><p>No specific information is available on the treatment of overdose with montelukast. It is not known whether montelukast is dialysable by peritoneal- or haemo-dialysis.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Leukotriene receptor antagonist ATC-Code: R03D C03</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent inflammatory eicosanoids released from various cells including mast cells and eosinophils. These important pro-asthmatic mediators bind to cysteinyl leukotriene receptors (CysLT) found in the human airway and cause airway actions, including bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1&nbsp;receptor. In clinical studies, montelukast inhibits bronchoconstriction due to inhaled LTD4&nbsp;at doses as low as 5 mg. Bronchodilation was observed within 2 hours of oral administration. The bronchodilation effect caused by a b-agonist was additive to that caused by montelukast. Treatment with montelukast inhibited both early- and late-phase bronchoconstriction due to antigen challenge. Montelukast, compared with placebo, decreased peripheral blood eosinophils in adult and paediatric&nbsp; patients. In a&nbsp; separate&nbsp; study, treatment with montelukast significantly decreased eosinophils in the airways (as measured in sputum). In adult and paediatric patients 2 to 14 years of age, montelukast, compared with placebo, decreased peripheral blood eosinophils while improving clinical asthma control.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>In studies in adults, montelukast, 10 mg once daily, compared with placebo, demonstrated significant improvements in morning FEV1 (10.4% vs 2.7% change from baseline), AM peak expiratory flow rate (PEFR) (24.5 L/min vs 3.3 L/min change from baseline), and significant decrease&nbsp; in total b-agonist use&nbsp; (-26.1% vs -4.6% change from baseline). Improvement in patient-reported daytime and &nbsp;nighttime asthma symptoms scores was significantly better than placebo.</p><p>&nbsp;</p><p>Studies in adults demonstrated the ability of montelukast to add to the clinical effect of inhaled corticosteroid (% change from baseline for inhaled beclomethasone plus montelukast vs beclomethasone, respectively for FEV1:&nbsp;5.43% vs 1.04%; b-agonist use: -8.70% vs 2.64%). Compared with inhaled beclomethasone (200 mg twice daily with a spacer device), montelukast demonstrated a more rapid initial response, although over the 12-week study, beclomethasone provided a greater average treatment effect (% change from baseline for montelukast vs beclomethasone, respectively for FEV1:&nbsp;7.49% vs 13.3%; b-agonist use: -28.28% vs -43.89%). However, compared with beclomethasone, a high percentage of patients treated with montelukast achieved similar clinical responses (e.g., 50% of patients treated with beclomethasone achieved an improvement in FEV1&nbsp;of approximately 11% or more over baseline while approximately 42% of patients treated with montelukast achieved the same response).</p><p>&nbsp;</p><p>In a 12-week, placebo-controlled study in paediatric patients 2 to 5 years of age, montelukast 4 mg once daily improved parameters of asthma control compared with placebo irrespective of concomitant controller therapy (inhaled/nebulised corticosteroids or inhaled/nebulised sodium cromoglycate). Sixty percent of patients were not on any other controller therapy. Montelukast improved daytime symptoms (including coughing, wheezing, trouble breathing and activity limitation) and nighttime symptoms compared with placebo. Montelukast also decreased &ldquo;as needed&rdquo;</p><p>b-agonist use and corticosteroid rescue for worsening asthma compared with placebo.</p><p>&nbsp;</p><p>Patients receiving montelukast had more days without asthma than those receiving placebo. A treatment effect was achieved after the first dose.</p><p>&nbsp;</p><p>In a 12-month, placebo-controlled study in paediatric patients 2 to 5 years of age with mild asthma and episodic exacerbations, montelukast 4 mg once daily significantly (p&le;0.001) reduced the yearly rate of asthma exacerbation episodes (EE) compared with placebo (1.60 EE vs. 2.34 EE, respectively), [EE defined as &ge;3 consecutive days with daytime symptoms requiring &beta;-agonist use, or corticosteroids (oral or inhaled), or hospitalisation for asthma]. The percentage reduction in yearly EE rate was 31.9%, with a 95% CI of 16.9, 44.1.</p><p>&nbsp;</p><p>In a placebo-controlled study in paediatric patients 6 months to 5 years of age who had intermittent asthma but did not have persistent asthma, treatment with montelukast was administered over a 12-month period, either as a once-daily 4 mg regimen or as a series of 12-day courses that each were started when an episode of intermittent symptoms began. No significant difference was observed between patients treated with montelukast 4 mg or placebo in the number of asthma episodes culminating in an asthma attack, defined as an asthma episode requiring utilization of health-care resources such as an unscheduled visit to&nbsp; a doctor&rsquo;s office, emergency room,&nbsp; or hospital; or treatment with oral, intravenous, or intramuscular corticosteroid.</p><p>&nbsp;</p><p>In an 8-week study in paediatric patients 6 to 14 years of age, montelukast 5 mg once daily, compared with placebo, significantly improved respiratory function (FEV1&nbsp;8.71% vs 4.16% change from baseline; AM PEFR 27.9 L/min vs 17.8 L/min change from baseline) and decreased &ldquo;as-needed&rdquo; b-agonist use (-11.7% vs +8.2% change from baseline).</p><p>&nbsp;</p><p>In a 12-month study comparing the efficacy of montelukast to inhaled fluticasone on asthma control in paediatric patients 6 to 14 years of age with mild persistent asthma, montelukast was non-inferior to fluticasone in increasing the percentage of asthma rescue-free days (RFDs), the primary endpoint.&nbsp; Averaged over the 12-month treatment period, the percentage of asthma RFDs increased from 61.6 to 84.0 in the montelukast group and from 60.9 to 86.7 in the fluticasone group. The between group difference in LS mean increase in the percentage of asthma RFDs was statistically significant (-2.8 with a 95% CI of -4.7, -0.9), but within the limit pre-defined to be clinically not inferior. Both montelukast and fluticasone also improved asthma control on secondary variables assessed over the 12 month treatment period:</p><p>FEV1&nbsp;&nbsp;increased from 1.83 L to 2.09 L in the montelukast group and from 1.85 L to</p><p>2.14 L in the fluticasone group. The between-group difference in LS mean increase in FEV1&nbsp;was -0.02 L with a 95% CI of -0.06, 0.02. &nbsp;The mean increase from baseline in</p><p>% predicted FEV1&nbsp;was 0.6% in the montelukast treatment group, and 2.7% in the fluticasone treatment group. The difference in LS means for the change from baseline in the % predicted FEV1&nbsp;was significant: -2.2% with a 95% CI of -3.6, -0.7.</p><p>The percentage of days with b-agonist use decreased from 38.0 to 15.4 in the montelukast group, and from 38.5 to 12.8 in the fluticasone group. The between group difference in LS means for the percentage of days with &beta;-agonist use was significant: 2.7 with a 95% CI of 0.9, 4.5.</p><p>The percentage of patients with an asthma attack (an asthma attack being defined as a period of worsening asthma that required treatment with oral steroids, an unscheduled visit to the doctor&rsquo;s office, an emergency room visit, or hospitalisation) was 32.2 in the</p><p>&nbsp;</p><p>montelukast group and 25.6 in the fluticasone group; the odds ratio (95% CI) being significant: equal to 1.38 (1.04, 1.84).</p><p>The percentage of patients with systemic (mainly oral) corticosteroid use during the study period was 17.8% in the montelukast group and 10.5% in the fluticasone group. The between group difference in LS means was significant: 7.3% with a 95% CI of 2.9; 11.7.</p><p>&nbsp;</p><p>Significant reduction of exercise-induced bronchoconstriction (EIB) was demonstrated in a 12-week study in adults (maximal fall in FEV1&nbsp;22.33% for montelukast vs 32.40% for placebo; time to recovery to within 5% of baseline FEV1&nbsp;44.22 min vs 60.64 min). This effect was consistent throughout the 12-week study period. Reduction in EIB was also demonstrated in a short term study in paediatric patients 6 to 14 years of age (maximal fall in FEV1&nbsp;18.27% vs 26.11%; time to recovery to within 5% of baseline FEV1&nbsp;17.76 min vs 27.98 min). The effect in both studies was demonstrated at the end of the once-daily dosing interval.</p><p>&nbsp;</p><p>In aspirin-sensitive asthmatic patients receiving concomitant inhaled and/or oral corticosteroids, treatment with montelukast, compared with placebo, resulted in significant improvement in asthma control (FEV1 8.55% vs -1.74% change from baseline and decrease in total b-agonist use -27.78% vs 2.09% change from baseline).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Absorption</u></p><p>Montelukast is rapidly absorbed following oral administration. For the 10 mg film- coated tablet, the mean peak plasma concentration (Cmax) is achieved 3 hours (Tmax) after administration in adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and Cmax&nbsp;are not influenced by a standard meal. Safety and efficacy were demonstrated in clinical trials where the 10 mg film-coated tablet was administered without regard to the timing of food ingestion.</p><p>&nbsp;</p><p>For the 5 mg chewable tablet, the Cmax&nbsp;is achieved in 2 hours after administration in adults in the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a standard meal.</p><p>&nbsp;</p><p>After administration of the 4 mg chewable tablet to paediatric patients 2 to 5 years of age in the fasted state, Cmax&nbsp;&nbsp;is achieved 2 hours after administration. &nbsp;The mean Cmax&nbsp;is 66% higher while mean Cmin&nbsp;is lower than in adults receiving a 10 mg tablet.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Montelukast is more than 99% bound to plasma proteins. The steady-state volume of distribution of montelukast averages 8-11 litres. Studies in rats with radiolabelled montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabelled material at 24 hours post-dose were minimal in all other tissues.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Montelukast is extensively metabolised. In studies with therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and children.</p><p>&nbsp;</p><p>Cytochrome P450 2C8 is the major enzyme in the metabolism of montelukast. Additionally CYP 3A4 and 2C9 may have a minor contribution, although itraconazole, an inhibitor of CYP 3A4, was shown not to change pharmacokinetic variables of montelukast in healthy subjects that received 10 mg montelukast daily. Based on <em>in vitro </em>results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. The contribution of metabolites to the therapeutic effect of montelukast is minimal.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The plasma clearance of montelukast averages 45 ml/min in healthy adults. Following an oral dose of radiolabelled montelukast, 86% of the radioactivity was recovered in 5- day faecal collections and &lt;0.2% was recovered in urine. Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile.</p><p>&nbsp;</p><p><u>Characteristics in Patients</u></p><p>No dosage adjustment is necessary for the elderly or mild to moderate hepatic insufficiency. Studies in patients with renal impairment have not been undertaken. Because montelukast and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to be necessary in patients with renal impairment. There are no data on the pharmacokinetics of montelukast in patients with severe hepatic insufficiency (Child-Pugh score &gt;9).</p><p>&nbsp;</p><p>With high doses of montelukast (20- and 60-fold the recommended adult dose), a decrease in plasma theophylline concentration was observed. This effect was not seen at the recommended dose of 10 mg once daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal toxicity studies, minor serum biochemical alterations in ALT, glucose, phosphorus and triglycerides were observed which were transient in nature. The signs of toxicity in animals were increased excretion of saliva, gastro-intestinal symptoms, loose stools and ion imbalance. These occurred at dosages which provided &gt;17-fold the systemic exposure seen at the clinical dosage. In monkeys, the adverse effects appeared at doses from 150 mg/kg/day (&gt;232-fold the systemic exposure seen at the clinical dose). In animal studies, montelukast did not affect fertility or reproductive performance at systemic exposure exceeding the clinical systemic exposure by greater than 24-fold. A slight decrease in pup body weight was noted in the female fertility study in rats at 200 mg/kg/day (&gt;69-fold the clinical systemic exposure). In studies in rabbits, a higher incidence of incomplete ossification, compared with concurrent control animals, was seen at systemic exposure &gt;24-fold the clinical systemic exposure seen at the clinical dose. No abnormalities were seen in rats. Montelukast has been shown to cross the placental barrier and is excreted in breast milk of animals.</p><p>&nbsp;</p><p>No deaths occurred following a single oral administration of montelukast sodium at doses up to 5,000 mg/kg in mice and rats (15,000 mg/m2&nbsp;and 30,000 mg/m2 in mice and rats, respectively), the maximum dose tested. This dose is equivalent to 25,000 times the recommended daily adult human dose (based on an adult patient weight of 50 kg).</p><p>&nbsp;</p><p>Montelukast was determined not to be phototoxic in mice for UVA, UVB or visible light spectra at doses up to 500 mg/kg/day (approximately &gt;200-fold based on systemic exposure).</p><p>&nbsp;</p><p>Montelukast was neither mutagenic in <em>in vitro </em>and <em>in vivo </em>tests nor tumorigenic in rodent species.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if !supportLists]-->1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->List of excipients</p><p><strong>&nbsp;</strong></p><p>Mannitol (E 421)</p><p>Microcrystalline cellulose Hyprolose (E 463)</p><p>Red ferric oxide (E 172) Croscarmellose sodium Cherry flavour Aspartame (E 951) Magnesium stearate</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from light and moisture.</p><p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Packaged in polyamide/PVC/aluminium blister package in:</p><p>Blisters in packages of: 7, 10, 14, 20, 28, 30, 50, 56, 98, 100, 140 and 200 tablets. Blisters (unit doses), in packages of: 49x1, 50x1 and 56x1 tablets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder: 
Merck Sharp & Dohme Limited, Hertford Road,
Hoddesdon, Hertfordshire EN11 9BU,
UK.

Manufacturer:
Merck Sharp & Dohme Limited, Shotton Lane, 
Cramlington, Northumberland, NE23 3JU, 
UK.

Packed by:
Pharma Pharmaceutical Industries,
Second Industrial Area,
P.O. Box 11351 Riyadh, Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 DATE OF REVISION OF THE TEXT 19 August 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>